Ritodrine

	WikiDoc Resources for Ritodrine
Articles
Most recent articles on Ritodrine Most cited articles on Ritodrine Review articles on Ritodrine Articles on Ritodrine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ritodrine Images of Ritodrine Photos of Ritodrine Podcasts & MP3s on Ritodrine Videos on Ritodrine
Evidence Based Medicine
Cochrane Collaboration on Ritodrine Bandolier on Ritodrine TRIP on Ritodrine
Clinical Trials
Ongoing Trials on Ritodrine at Clinical Trials.gov Trial results on Ritodrine Clinical Trials on Ritodrine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ritodrine NICE Guidance on Ritodrine NHS PRODIGY Guidance FDA on Ritodrine CDC on Ritodrine
Books
Books on Ritodrine
News
Ritodrine in the news Be alerted to news on Ritodrine News trends on Ritodrine
Commentary
Blogs on Ritodrine
Definitions
Definitions of Ritodrine
Patient Resources / Community
Patient resources on Ritodrine Discussion groups on Ritodrine Patient Handouts on Ritodrine Directions to Hospitals Treating Ritodrine Risk calculators and risk factors for Ritodrine
Healthcare Provider Resources
Symptoms of Ritodrine Causes & Risk Factors for Ritodrine Diagnostic studies for Ritodrine Treatment of Ritodrine
Continuing Medical Education (CME)
CME Programs on Ritodrine
International
Ritodrine en Espanol Ritodrine en Francais
Business
Ritodrine in the Marketplace Patents on Ritodrine
Experimental / Informatics
List of terms related to Ritodrine

Ritodrine
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of; administration	Oral, parenteral
ATC code	G02CA01 (WHO) ;
Pharmacokinetic data
Protein binding	~56%
Elimination half-life	1.7-2.6 hours
Identifiers
	IUPAC name 4-(2-((1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-ylamino)ethyl)phenol;
CAS Number	26652-09-5 ;
PubChem CID	33572;
DrugBank	DB00867 ;
ChemSpider	30971 ;
UNII	I0Q6O6740J;
KEGG	D02359 ;
ChEMBL	ChEMBL785 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C17H21NO3
Molar mass	287.354 g/mol
3D model (JSmol)	Interactive image;
	SMILES O[C@H](c1ccc(O)cc1)[C@@H](NCCc2ccc(O)cc2)C;
	InChI InChI=1S/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1 ; Key:IOVGROKTTNBUGK-SJCJKPOMSA-N ;
(verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ritodrine (discontinued preparation: Yutopar) is a tocolytic drug, used to stop premature labor.^[1] This drug has been removed from the US market, according to FDA Orange Book. It was available in oral tablets or as an injection and was typically used as the hydrochloride salt, ritodrine hydrochloride.

Mechanism

Ritodrine is a beta-2 adrenergic receptor agonist - a class of medication used for smooth muscle relaxation (other similar drugs are used in asthma or other pulmonary diseases such as salbutamol). Since ritodrine has a bulky N-substituent, it has high β2-selectivity. Also, the 4'-hydroxy on the benzene ring is important for activity as it is needed to form hydrogen bonds. However, the 4'-hydroxy makes it susceptible to metabolism by COMT. Since it is β2-selective it is used for premature labor.^[2]

Side effects and potential contraindications

Most side effects of beta-2 agonists result from their concurrent beta-1 activity, and include increase in heart rate, rise in systolic pressure, decrease in diastolic pressure, chest pain secondary to MI, and arrhythmia. Beta agonists may also cause fluid retention secondary to decrease in water clearance, which when added to the tachycardia and increased myocardial work, may result in cardiac failure. In addition, they increase gluconeogenesis in the liver and muscle resulting in hyperglycemia, which increases insulin requirements in diabetic patients. The passage of beta-agonists through the placenta does occur and may be responsible for fetal tachycardia, as well as hypoglycemia or hyperglycemia at birth.

Patients with type 2 diabetes, high blood pressure or migraines should bring this to their doctor's attention before receiving care.

It has also been associated with post-partum hemorrhage.^{[citation needed]}

References

↑ Li X, Zhang Y, Shi Z (February 2005). "Ritodrine in the treatment of preterm labour: a meta-analysis" (PDF). The Indian journal of medical research. 121 (2): 120–7. PMID 15756046.
↑ Medicinal Chemistry of Adrenergics and Cholinergics

Template:Other gynecologicals

[pmid15756046-1] Li X, Zhang Y, Shi Z (February 2005). "Ritodrine in the treatment of preterm labour: a meta-analysis" (PDF). The Indian journal of medical research. 121 (2): 120–7. PMID 15756046.

[2] Medicinal Chemistry of Adrenergics and Cholinergics

[1]

[2]

v t e Adrenergic agonists
α	Template:Navbox subgroup
β	Template:Navbox subgroup
α and β	Epinephrine - Norepinephrine - Cirazoline - Etilefrine
Indirect/ mixed	Amphetamine - Tyramine - Ephedrine - Pseudoephedrine
see also acetylcholinesterase inhibitor

Clinical data

AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of administration	Oral, parenteral
ATC code	G02CA01 (WHO)
Pharmacokinetic data
Protein binding	~56%
Elimination half-life	1.7-2.6 hours
Identifiers
IUPAC name 4-(2-((1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-ylamino)ethyl)phenol
CAS Number	26652-09-5^Y
PubChem CID	33572
DrugBank	DB00867^Y
ChemSpider	30971^Y
UNII	I0Q6O6740J
KEGG	D02359^Y
ChEMBL	ChEMBL785^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₇H₂₁NO₃
Molar mass	287.354 g/mol
3D model (JSmol)	Interactive image
SMILES O[C@H](c1ccc(O)cc1)[C@@H](NCCc2ccc(O)cc2)C
InChI InChI=1S/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1^Y Key:IOVGROKTTNBUGK-SJCJKPOMSA-N^Y
(verify)

Ritodrine

Overview

Mechanism

Side effects and potential contraindications

References

Navigation menu